Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neuroblastoma 1Medulloblastoma 1Lymphoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 53Etoposide 33Temozolomide 28Irinotecan 28Melphalan 25Filgrastim 25Topotecan 24Carboplatin 243-Iodobenzylguanidine 23Isotretinoin 20Granulocyte Colony-Stimulating Factor 17sargramostim 16humanized 3F8 anti-GD2 monoclonal antibody 16dinutuximab 16Granulocyte-Macrophage Colony-Stimulating Factor 16fludarabine 15Vincristine 15Doxorubicin 15Cisplatin 15Peripheral Blood Stem Cell Transplantation 14Interleukin-2 14Busulfan 13naxitamab 12Thiotepa 12Radiotherapy 12aldesleukin 11fludarabine phosphate 10etoposide phosphate 8Mesna 8Ifosfamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroblastoma × CUDC-907 × Clear all
NCT02909777 2026-02-11

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Dana-Farber Cancer Institute

Phase 1 Completed
26 enrolled
CNSLymphoid

Brain Neoplasms, Lymphoma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡